3,5-diethyl 4-{2-[(1E)-3-(tert-butoxy)-3-oxoprop-1-en-1-yl]phenyl}-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate

• ChemBase编号: 73234
• 分子式: C26H33NO6
• 平均质量: 455.54332
• 单一同位素质量: 455.23078778
• SMILES: c1cccc(c1C1C(=C(NC(=C1C(=O)OCC)C)C)C(=O)OCC)/C=C/C(=O)OC(C)(C)C
• Canonical SMILES: CCOC(=O)C1=C(C)NC(=C(C1c1ccccc1/C=C/C(=O)OC(C)(C)C)C(=O)OCC)C
• InChI: InChI=1S/C26H33NO6/c1-8-31-24(29)21-16(3)27-17(4)22(25(30)32-9-2)23(21)19-13-11-10-12-18(19)14-15-20(28)33-26(5,6)7/h10-15,23,27H,8-9H2,1-7H3/b15-14+
• InChIKey: GKQPCPXONLDCMU-CCEZHUSRSA-N

名称和登记号

名称

• IUPAC标准名: 3,5-diethyl 4-{2-[(1E)-3-(tert-butoxy)-3-oxoprop-1-en-1-yl]phenyl}-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
• IUPAC传统名: caldine; lacidipine
• 别名: Lacipil; Motens; Lacidipine; (E)-4-[2-[3-(1,1-Dimethylethoxy)-3-oxo-1-propenyl]phenyl]-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic Acid Diethyl Ester, GR-43659X, GX-1048, Caldine, Lacipil, Lacirex, Motens

登记号

• CAS号: 103890-78-4
• PubChem SID: 162038154
• PubChem CID: 5311217

理论计算性质

• 质子受体: 4
• 质子供体: 1
• LogD (pH = 5.5): 3.9171872
• LogD (pH = 7.4): 4.1805105
• Log P: 4.1851535
• 摩尔折射率: 129.9138 cm^3
• 极化性: 49.212093 Å^3
• 极化表面积: 90.93 Å^2
• 可自由旋转的化学键: 11
• 里宾斯基五规则: true

分子性质

理化性质

• 溶解度: Chloroform
• 外观: White-to-Off-White Crystalline Solid
• 熔点: 174-175°C

安全信息

• 保存条件: -20°C; -20°C Freezer

药理学性质

• 作用靶点: calcium channel

产品相关信息

• 成盐信息: Free Base

详细说明

Selleck Chemicals - S1994

Research Area: Cancer
Biological Activity:
Lacidipine (Lacipil, Motens) is a L-type calcium channel blocker. Lacidipine (Lacipil, Motens) works by relaxing and opening up the blood vessels. [1] This allows blood to circulate more freely around the body, lowering blood pressure and allowing the heart to work more efficiently.Lacidipine (Lacipil, Motens) also inhibits Ca2+ (ER) efflux and enhances folding, trafficking, and activity of degradation-prone GC variants. Lacidipine (Lacipil, Motens) remodels mutated GC proteostasis by simultaneously activating a series of distinct molecular mechanisms, namely modulation of Ca2+ homeostasis, upregulation of the ER chaperone BiP, and moderate induction of the unfolded protein response. However, unlike previously reported proteostasis regulators, lacidipine (Lacipil, Motens) treatment is not cytotoxic but inhibits apoptosis induction typically associated with sustained activation of the unfolded protein response. [2] In another study, lacidipine pre-treatment prevents deterioration of motor nerve conduction velocity as compared to streptozotocin diabetic rats. Hyperalgesia induces by streptozotocin was antagonized by lacidipine (Lacipil, Motens). [3]References on Lacidipine (Lacipil, Motens)[1] http://en.wikipedia.org/wiki/Lacidipine, , [2] Chem Biol. , 2011 Jun 24, 18(6):766-76.[3] Arch Physiol Biochem., 2011 Feb, 117(1):12-7

Toronto Research Chemicals - L098000

A dihydropyridine calcium channel blocker. Antihypertensive.

参考文献

• Wang F, et al. Chem Biol. 2011 Jun 24;18(6):766-76.
• Safar, M., et al.: Clin. Pharmacol. Ther., 46, 94 (1989)
• Kharat, V.R., et al.: J. Pharm. Biomed. Anal., 28, 789 (1989)
• McCormack, A.J., et al.: Drugs, 63, 2327 (1989)